At a Glance
- Company: Gilead Sciences; Ouro Medicines
- Location: California (Gilead); US-based (Ouro)
- Deal value: Up to $2.2 billion (upfront plus milestones)
- Focus area: Oral macrocyclic peptides for difficult protein targets
- Next steps: Integrate Ouro’s platform into Gilead R&D; advance lead assets
What happened?
Gilead Sciences announced an agreement to acquire Ouro Medicines in a deal valued at up to $2.2 billion. The transaction brings Ouro’s proprietary macrocyclic peptide platform into Gilead, enabling oral delivery of large-molecule-like therapeutics for challenging protein targets.
Why does it matter?
Macrocyclic peptides bridge small molecules and biologics, offering oral bioavailability with the ability to target protein-protein interactions that traditional drugs cannot reach. This acquisition gives Gilead a differentiated platform to address undruggable targets in oncology, inflammation and beyond, positioning it to compete in next-generation modalities amid growing demand for oral alternatives to injectables.
Who’s behind it?
Ouro Medicines develops orally bioavailable macrocycles using computational design and proprietary chemistry to create conformationally constrained peptides that bind intracellular targets. Gilead gains the full platform and pipeline, including preclinical assets, to bolster its research capabilities across therapeutic areas.
How was it achieved?
Ouro’s technology generates macrocycles with optimised ADME properties, high potency and selectivity for protein interfaces. The deal structure includes upfront cash plus development and commercial milestones, reflecting standard big pharma biotech acquisition terms for high-potential platforms.
What’s next?
Gilead will integrate Ouro’s team and technology into its R&D organisation, with initial focus on advancing lead macrocycle candidates toward IND-enabling studies. Expect platform-wide expansion into Gilead’s priority areas, potentially yielding first clinical data within 2–3 years.